Sign In
Buy LUMO
$4.34
+0 (+0%)
At Close: Mar 10, 2025
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
04:05pm, Tuesday, 09'th Mar 2021
AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results fo
AUSTIN, Texas, March 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will present poster 7102 at th
Will Lumos Pharma (LUMO) Report Negative Earnings Next Week? What You Should Know
01:38pm, Tuesday, 02'nd Mar 2021
Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
04:15pm, Monday, 22'nd Feb 2021
AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report
Lumos Pharma (LUMO) in Focus: Stock Moves 8.3% Higher
09:47am, Friday, 18'th Dec 2020
Lumos Pharma (LUMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference
09:00am, Friday, 18'th Dec 2020
AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumo s Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company wi
Lumos Pharma to Participate in December Investor Conferences
07:43pm, Monday, 23'rd Nov 2020
AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company wil
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2020 Results - Earnings Call Transcript
08:44pm, Tuesday, 10'th Nov 2020
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2020 Results - Earnings Call Transcript
Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results
04:01pm, Tuesday, 10'th Nov 2020
AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results f
Lumos Pharma to Participate in November Investor Conferences
09:00am, Thursday, 29'th Oct 2020
AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
04:01pm, Tuesday, 27'th Oct 2020
AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report
Malaysia's EPF becomes Riverstone substantial shareholder
09:50pm, Sunday, 27'th Sep 2020
FOR the five local trading sessions that spanned Sept 18 to 24, the Straits Times Index (STI) declined 2.0 per cent, with the Nikkei 225 Index, Hang Seng Index and S&P/ASX 200 Index averaging a 1.8 pe
Lumos Pharma, Inc. 2020 Q2 - Results - Earnings Call Presentation
12:51pm, Friday, 14'th Aug 2020
The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2020 Q2 earnings call..
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
08:01pm, Thursday, 13'th Aug 2020
* Lumos Pharma sells Priority Review Voucher (PRV), valued at $100 million - Lumos Pharma to receive $60 million for its 60% interest in PRV * Lumos Pharma reaffirms its expectation of the initiation
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2020 Results - Earnings Call Transcript
07:10pm, Thursday, 13'th Aug 2020
Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2020 Earnings Conference Call August 13, 2020 4:30 p.m.
